[On the multiple-dose kinetics of glibornuride in man (author's transl)].
The multiple-dose pharmacokinetics of 1-(2-endo-hydroxy-3-endo-bornyl)-3-(p-tolyl-sulfonyl)-urea (glibornuride, Glutril¿) was examined in 7 subjects with maturity-onset diabetes treated with the drug over a period of 4 weeks (25 mg every twelve hours). The steady-state levels of glibornuride (maximum and minimum concentrations) were determined experimentally and by calculation (using the pharmacokinetic parameters obtained following oral administration of 50 mg glibornuride on the 1st day of the treatment). There was good agreement between experimental and calculated values. The results afford evidence for the regular pharmacokinetic pattern of glibornuride. There was neither unexpected accumulation of the drug nor diminution of the steady-state levels as might occur as a consequence of induction of microsomal enzymes.
D001682:Biological Availability; D003920:Diabetes Mellitus / Q000188:drug therapy*; D006801:Humans; D007700:Kinetics; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000097:blood*
D013453:Sulfonylurea Compounds
Mehrdosenkinetik von Glibornurid beim Menschen